Press Releases June 24, 2026 07:05 AM

OrthoPediatrics Announces Distribution Agreement with OSSIO, Inc. to Provide Revolutionary Orthopedic Fixation Technology to U.S. Children’s Hospitals Nationwide

OrthoPediatrics Partners with OSSIO to Distribute Innovative Metal-Free Fixation Implants to U.S. Children's Hospitals

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
KIDS

OrthoPediatrics Corp. has entered into an exclusive distribution agreement with OSSIO, Inc. to provide their innovative bio-integrative, metal-free OSSIOfiber implants to children's hospitals across the United States. These implants offer a significant advancement in pediatric orthopedic care by reducing the need for secondary surgeries associated with traditional metal implants, as they gradually integrate into the patient's bone. This partnership complements OrthoPediatrics' existing product portfolio and is expected to expand their market presence and growth prospects.

OrthoPediatrics Announces Distribution Agreement with OSSIO, Inc. to Provide Revolutionary Orthopedic Fixation Technology to U.S. Children’s Hospitals Nationwide
KIDS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Exclusive U.S. distribution agreement with OSSIO for bio-integrative, metal-free OSSIOfiber implants designed for pediatric orthopedic fixation.
  • OSSIOfiber implants provide comparable strength to metal implants but integrate into bone over 18-24 months, reducing secondary hardware removal surgeries.
  • The partnership enhances OrthoPediatrics' pediatric orthopedic product offerings, potentially increasing market reach and addressing more unmet patient needs.
  • Sectors impacted include medical devices, pediatric healthcare, and orthopedic surgery markets.

WARSAW, Ind., June 24, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced an exclusive distribution agreement with OSSIO, Inc. (“OSSIO”) that brings U.S. children’s hospitals nationwide a bio-integrative, metal-free fixation technology ideally suited for treatment of fractures and deformities in pediatric patients.

After performing their fixation function, OSSIOfiber® implants are gradually replaced by the patient’s newly formed bone during the natural healing process. This technological advance in material science decreases the need for hardware removal surgeries that pediatric patients who initially receive metal implants usually receive.

“Existing fixation technology requires pediatric orthopedic surgeons to consistently remove their patients’ metal implants in a second surgery that adds cost and risk,” said Joe Hauser, President of Trauma and Deformity at OrthoPediatrics. “OSSIOfiber implants reduce the rate of these secondary procedures by doing away with metal. From a strategic perspective, partnering with OSSIO expands our reach and capabilities with a revolutionary technology that complements OrthoPediatrics’ current product offering, allowing us to address more unmet pediatric needs while strengthening the company’s long-term growth potential.”

OSSIOfiber implants are made from a proprietary blend of natural mineral fibers that provide initial fixation strength comparable to traditional metal implants while safely and completely integrating into the patient’s own bone tissue within 18–24 months post-implantation, leaving no hardware behind.

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets nearly 90 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.

Investor Contact
Philip Trip Taylor
Gilmartin Group
[email protected]
415-937-5406


Risks

  • The new OSSIOfiber technology, while promising, may face adoption challenges among pediatric orthopedic surgeons accustomed to traditional metal implants.
  • Regulatory or reimbursement hurdles could impact the rollout and acceptance of new implant technologies in hospital settings.
  • Competition from other orthopedic fixation technologies and companies may limit market penetration and growth potential for OSSIOfiber implants.

More from Press Releases

Correction: WISeKey and Its Subsidiary WISeSat.Space Corp. Announce Filing of Registration Statement on Form F-4 with the U.S. Securities and Exchange Commission Jun 24, 2026 RoboStrategy, Inc. Updates Net Asset Value as of June 22, 2026 Jun 24, 2026 RedCloud Signs Up to $120M India Joint Venture, to Deploy Its RAID Engine Into FMCG, Apparel and Footwear Categories Jun 24, 2026 NextNRG's EzFill Expects to Deliver More Than 50,000 Gallons Supporting Generator Operations at Major International Soccer Tournament in Miami Jun 24, 2026 Fabric.AI (Nasdaq: FABC) Stockholders Ratify Kopin Strategic Partnership to Develop Neural I/o™ MicroLED Optical Interconnect Technology for Next Generation AI Data Centers Jun 24, 2026